← Back to Clinical Trials
Recruiting NCT06370780

NCT06370780 Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06370780
Status Recruiting
Phase
Sponsor University of California, Los Angeles
Condition HIV Infections
Study Type INTERVENTIONAL
Enrollment 1,000 participants
Start Date 2024-02-09
Primary Completion 2028-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
EPI LOVE

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,000 participants in total. It began in 2024-02-09 with a primary completion date of 2028-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to HIV care including racial discrimination, stigma and rural isolation.

Eligibility Criteria

Inclusion Criteria: * Have access to a personal smartphone device; * Over 18 years of age; * Speak English or Spanish; * Living with HIV * Are either 1) not currently virally suppressed, 2) not currently engaged in care, or 3) have one or more factors associated with viral non suppression including a history of missed appointments or viral non suppression; * Active substance use or mental health disorder; * Willing and able to provide written informed consent to take part in the study. Exclusion Criteria: * Unwilling or unable to provide reliable contact information; * Unwilling to provide blood sample for HIV virology testing; * Living with HIV and virally suppressed and not at risk of becoming unsuppressed in the near future.

Contact & Investigator

Central Contact

Pamina Gorbach, DrPh

✉ RemainApp@ph.ucla.edu

📞 (628) 226-1863

Principal Investigator

Pamina Gorbach, DrPh

PRINCIPAL INVESTIGATOR

University of California, Los Angeles

Frequently Asked Questions

Who can join the NCT06370780 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06370780 currently recruiting?

Yes, NCT06370780 is actively recruiting participants. Contact the research team at RemainApp@ph.ucla.edu for enrollment information.

Where is the NCT06370780 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT06370780 clinical trial?

NCT06370780 is sponsored by University of California, Los Angeles. The principal investigator is Pamina Gorbach, DrPh at University of California, Los Angeles. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology